Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608439 · ClinicalTrials.gov registry record · Phase 2
Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy
A Phase 2 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00608439 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 43 participants.
The verdict
NCT00608439, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this protocol is to investigate the safety, tolerability and effectiveness of CAST as a treatment for diabetic neuropathy. The primary outcome measure will be Total Neuropathic Symptom Score. Secondary outcomes will be neurological disability score, nerve conduction measurements and quantitative sensory testing. Statistical analyses will compare changes from baseline for CAST- and placebo-treated groups at both time points, compare effects of CAST at 6 and 12 months and, if numbers permit, compare doses.
Interventions
- OTHER Placebo
- DRUG Centella asiatica selected triterpenes (CAST)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608439
The ClinicalTrials.gov registry entry for NCT00608439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00608439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608439 about?
NCT00608439 is a clinical study titled "Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy". The purpose of this protocol is to investigate the safety, tolerability and effectiveness of CAST as a treatment for diabetic neuropathy. The primary outcome measure will be Total Neuropathic Symptom Score. Secondary outcomes will be neurological disability score, nerve conduction measurements and q...
What is the current status of trial NCT00608439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2007-09. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00608439?
The interventions under investigation include: Placebo (OTHER), Centella asiatica selected triterpenes (CAST) (DRUG).
Who is sponsoring clinical trial NCT00608439?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.